TY - JOUR T1 - MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients JF - Cancer Genomics - Proteomics JO - Cancer Genomics Proteomics SP - 353 LP - 359 DO - 10.21873/cgp.20140 VL - 16 IS - 5 AU - JULIA KOVACOVA AU - JAROSLAV JURACEK AU - ALEXANDR POPRACH AU - JINDRICH KOPECKY AU - ONDREJ FIALA AU - MAREK SVOBODA AU - PAVEL FABIAN AU - LENKA RADOVA AU - PETR BRABEC AU - TOMAS BUCHLER AU - ONDREJ SLABY Y1 - 2019/09/01 UR - http://cgp.iiarjournals.org/content/16/5/353.abstract N2 - Background/Aim: Sunitinib is a tyrosine kinase inhibitor routinely used as first-line therapy in metastatic renal cell carcinoma (mRCC). Emerging evidence suggests that microRNAs (miRNAs) could be suitable biomarkers with predictive potential in mRCC. The aim of this study was to identify miRNA-based predictive biomarkers of therapy response to avoid unnecessary therapy to non-responding patients. Patients and Methods: High-throughput miRNA microarray profiling was performed on a cohort of 47 patients treated with sunitinib. Validation of candidate miRNAs was carried out on an independent cohort of 132 mRCC patients using qRT-PCR. Results: Out of 158 miRNAs (65 down-regulated, 93 up-regulated), six miRNAs were chosen for independent validation and miR-376b-3p was confirmed to be differentially expressed in tumors of patients with primary resistance versus long-term response (p<0.0002). Conclusion: A predictive miRNA associated with progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib was identified. ER -